News
Tolebrutinib did not show superiority over Aubagio (teriflunomide) in reducing relapse rates or MRI-detected inflammatory ...
Strategies for ensuring that innovation with PROs remains parallel with advancements in disease detection and progression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback